In this report from the AstraZeneca Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with HF(DETERMINE) trials, we describe the associations between wearable accelerometer-based measures of physical activity, HFcharacteristics, 6MWD, and PROMs, including the KCCQ in a contemporary cohort of patients with HF across the entire range of left ventricular ejec-tion fractions.